Compare ALMU & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALMU | ARMP |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.6M | 295.5M |
| IPO Year | N/A | 1996 |
| Metric | ALMU | ARMP |
|---|---|---|
| Price | $21.79 | $8.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $24.67 | $15.00 |
| AVG Volume (30 Days) | ★ 1.8M | 69.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.49 | N/A |
| Revenue Next Year | $60.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.20 | $1.74 |
| 52 Week High | $31.79 | $14.98 |
| Indicator | ALMU | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 42.01 |
| Support Level | $14.16 | $7.22 |
| Resistance Level | $22.12 | $8.40 |
| Average True Range (ATR) | 3.44 | 0.94 |
| MACD | -0.65 | 0.02 |
| Stochastic Oscillator | 22.23 | 49.17 |
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.